INTRODUCTION
Langerhans cell histiocytosis(LCH) have been an enigma since its discovery by Hand in 1893 (1) . It remained so for a very long time due to its wide clinical presentations, variable histopathological features and an uncertain aetiology. It was Lichtenstein in 1953 (2) who analyzed the range of clinical and pathological variations and concluded that the malady of diseases~were in fact a single entity and termed it "Histiocytosis X'. Histiocytosis for the proliferation of histiocyte-like cells while "X" denotes the unknown aetiology. Nezelof in 1973 (3) was first to identify that these proliferative histiocytes were Langerhans cells. Subsequent developments in immunocytochemistry have positively proven this by the discovery that these histiocytes share a common surface antigen with normal Langerhans cells, the CD Ia antigen (4). It is now accepted that Langerhans cell histiocytosis (LCH) is the most appropriate term to refer to the above disease.
CLINICOPATHOLOGICAL PRESENTATIONS Little is known of the epidemiology of LCH primarily because it is a relatively rare disease. However Cartensen and Ornvold (5) found that the incidence rate of LCH is 1.08 in 200,000 in a survey involving a total population of 1 million children under the age of 15 in Denmark. The incidence of adult however is more difficult to fathom due to wider clinical presentations, often symptomless and under reporting by clinical specialists.
LCH is classified traditionally into 3 distinctive clinical presentations. The mildest of which is termed eosinophilic granuloma where symptoms of solitary or multiple bone lesions are usually reported. The second is the chronic disseminated form of LCH which is classically known as Hand-Schuller-Christian syndrome characterized by a triad of symptoms which includes intraosseous lesion, exophthalmos and diabetes insipidus. The third is the acute or subacute form of the disease which is known as Letterer-Siwe syndrome. It is characterized by rapid onset with widespread skeletal and extraskeletal lesions. It occurs usually in infants less than 3 years of age with severe clinical course and sometimes results in a fabl outcome. Not all cases however satisfy the above criteria. Lieberman (6) proposed a simpler classification in which LCH is classified as having either a unifocal or multifocal entity.
The histological picture is possibly the common denominator of the above diseases. Under light microscopy, the lesion is often described as an aggregation of histiocytic like cells arranged in a sheet like fashion superimposed with eosinophils in a fibrous connective tissue matrix. Under electron microscopy, Birbecks granules are characteristically present. Immunohistochemistry would show a positive labelling for CD la surface antigen. Another alternative approach stipulated by the German-Italian prospective cooperative multicentre study group, the AIEOP-CNR-HX 83 (13), divides patients with multisystem disease into good and poor prognostic groups according to the absence or presence of organ dysfunction at the time of diagnosis. Treatment of good prognosis patients is to administer single agents sequentially to obtain favourable response. These are vinblastine (6.5 mg/m2 Lv. weekly for three months) followed by doxorubicin (20 mg/m2 i. v. for 2 consecutive days every 3 weeks for 3 months) and finally VPl6 (200 mg/m2 i.v. for 3 consecutive days, 3 weekly, at least for 3 months). For poor risk group, they will receive 9 courses of a 4 week treatment with a combination chemotherapy including vincristine, cydophosphamide, doxorubicin and prednisolone. This study concludes that response for single agents were effective in patient with good prognosis. In poor risk cases however, prognosis remain bad despite multi-agent therapy.
With greater understanding of the disease process researches have tried other approaches in the treatment of LCH. The Histiocyte Society have also established the Salvage Therapy Group to propose a study for the use of experimental drugs when the normal regimen have been proven ineffective (14) . These approaches include the use of cyclosporin A (15) on the rationale that selective inhibition of the cellular immune response and cytokine mediated cellular activation would suppress the immunoarculatory effect of the disease. Alpha interferon have also been used in the hope of increasing NK cytotoxic activity. There is a case report of success in using this approach (16) . However, no prospective clinical trial, as yet, have been initiated to show the efficacy of this form of treatment.
Bone marrow ablative therapy with bone marrow transplant (BMT) in the recurrent multisystem disease have been tried out in clinical practice A study (17) has reported some degree of success but the mortality rate due to either the recurrence of disease or the side effect of treatment is still unacceptably high. Monoctonal antibody therapy of LCH patients exploits the potential role of monoclonal antibody directed against the CD 1a surface antigen of Langerhans cells. Kelly and Pritchard (18) were first to investigate the possibility of such treatment. The clinical application potential of this technique is immense either through a cytotoxic or immunoregulatory mode of treatment.
CONCLUSION
Langerhans cell histiocytosis have puzzled clinicians and scientists alike. Recent scientific breakthrough have shown that it is of neoplastic origin rather than a reactive disease. Clinical diagnosis may be difficult and often it is the dental surgeon who are first in line to notice this disease. LCH may mimic a wide range of clinical entities. It may present itself as juvenile or refractory periodontitis. It may be present as diabetes insipidus or a clinical condition similar to lymphoma. Therefore suspicious localized or generalized periodontal pocketing or bone loss must be investigated and the differential diagnosis of LCH must not be discounted.
Treatment of LCH is a contentious issue. However the consensus is to divide patients into single or multiple systems group. The single system group is treated more conservatively with either curettage of the localised lesion, intralesional steroid injection or in some cases radiotherapy, if the lesion threatens any vital organs. For the multisystem group, a more comprehensive approach is implemented primarily utilising VPI6, vincristine or other chemotherapy agents as either a single or combination therapy. It must be pointed out that in situations where there is organ dysfunction, prognosis remain poor despite utilising all chemotherapy options. Novel therapeutics offer new potentials by opening new fronts in combatting LCH. This is only possible by further research in the quest for better understanding of this disease.
